New Summit data clouds approval pathway in lung cancer“A combination of ivonescimab and chemotherapy didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.” First-in-human trial shows promising results for...
The quality of patient decision aids for lung cancer screening: Results from an environmental scan“Shared decision making is recommended for lung cancer screening (LCS) by professional organizations and payers. Patient decision aids can be used to support shared...
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer“SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc....
Neoadjuvant Immunotherapy Shows Promise in Limited-Stage SCLC“Key Takeaways: Neoadjuvant chemoimmunotherapy in LS-SCLC shows high pCR and MPR rates, indicating promising efficacy before surgery. The meta-analysis found a 95% R0 surgical resection rate, with no...
Lung Cancer in Special Populations“Lung cancer is the leading cause of cancer deaths worldwide, claiming more lives than other age-related and screen-detectable cancers. Cigarette smoking remains the most important risk factor. However, despite common perceptions,...
Breakthrough lung cancer treatment supercharges immune cells with mitochondria “Scientists have found a way to supercharge lung cancer treatment by transplanting healthy mitochondria into tumors, which both boosts immune response and makes chemotherapy far more...
More News and Updates